Cases in which product prices rise very sharply are relatively infrequent and are likely to raise a red flag that something may be amiss.
The Competition and Markets Authority (CMA) has announced its finding that four pharmaceutical companies colluded over a five-year period not to compete with one another in the supply of an anti-nausea drug. The effect was an increase of 700 per cent in the sum paid by the NHS for the drug.
Action is being taken against the firms, and it is likely that the result will be punitive fines.
It should be remembered that any anti-competitive activity is unlawful under the Competition Act 1998 and can lead to substantial fines as well as the naming and shaming of the businesses involved.
If you are invited to join in anti-competitive activity or your business is being affected by anti-competitive activity, we can advise you of the appropriate steps to take.
For help and advice on Corporate and Commercial matters please contactus on 08081668827
 |
 |
 |
 |
 |
 |
|
